视神经脊髓炎相关视神经炎患者血清8-OHDG、VILIP-1水平变化及其意义

目的 探讨视神经脊髓炎相关视神经炎(NMO-ON)患者血清8-羟基脱氧鸟苷(8-OHDG)、视锥蛋白样蛋白-1(VILIP-1)水平与临床疗效以及复发的关系。方法 选择眼科收治的73例NMO-ON患者(NMO-ON组),根据水通道蛋白-4免疫球蛋白G抗体(AQP4-IgG)检测结果将NMO-ON患者分为AQP4-IgG阳性组(59例)和AQP4-IgG阴性组(14例),另选择49例健康志愿者为对照组。检测血清8-OHDG、VILIP-1水平，追踪NMO-ON患者临床治疗疗效，出院随访NMO-ON复发情况。结果 NMO-ON组基线血清8-OHDG、VILIP-1水平高于对照组(P<0.05),AQP4-IgG阳性组基线血清8-OHDG、VILIP-1水平高于AQP4-IgG阴性组(P<0.05)。NMO-ON患者治疗后血清8-OHDG、VILIP-1水平均较治疗前下降(P<0.05),73例NMO-ON患者治疗有效55例(有效组),无效18例(无效组),有效组治疗后血清8-OHDG、VILIP-1水平低于无效组(P<0.05)。随访失访3例，复发55例(复发组),...

Changes of serum 8-OHDG and VILIP-1 levels in patients with neuromyelitis optica associated with optic neuritis and their clinical significance

Objective To investigate the correlations between serum levels of 8-hydroxydeoxyguanosine (8-OHDG) and cone protein-like protein-1 (VILIP-1) and clinical efficacy and recurrence in patients with neuromyelitis optica associated optic neuritis (NMO-ON). Methods 73 NMO-ON patients (NMO-ON group) were selected. According to the results of aquaporin-4 immunoglobulin G antibody (AQP4-IgG) detection, NMO-ON patients were divided into AQP4-IgG positive group (59 cases) and AQP4-IgG negative group (14 cases). Another 49 healthy volunteers were selected as the control group. The levels of serum 8-OHDG and VILIP-1 were detected, and the clinical efficacy of NMO-ON patients was tracked. The recurrence of NMO-ON was followed up after discharge. Results The baseline serum levels of 8-OHDG and VILIP-1 in NMO-ON group were significantly higher than those in control group (P<0.05), and the baseline serum levels of 8-OHDG and VILIP-1 in AQP4-IgG positive group were significantly higher than those in AQP4-IgG negative group (P<0.05). The levels of serum 8-OHDG and VILIP-1 in patients with NMO-ON after treatment were significantly reduced compared with those before treatment (P<0.05). Of 73 patients with NMO-ON, treatment in 55 patients were effective (effective group) and in 18 patients were ineffective (ineffective group). The levels of serum 8-OHDG and VILIP-1 in the effective group were significantly lower than those in the ineffective group after treatment (P<0.05). Three patients were lost to follow-up, 55 patients had recurrence (recurrence group) and 15 patients did not relapse (non-recurrence group). The serum 8-OHDG and VILIP-1 levels in the non-recurrence group were significantly lower than those in the recurrence group after treatment (P<0.05). The area under the curve of combined baseline 8-OHDG and VILIP-1 in the diagnosis of NMO-ON was 0.856, which was significantly higher than that of 8-OHDG or VILIP-1 alone (0.731 or 0.702, P<0.05). The areas under the curve of 8-OHDG and VILIP-1 in the prediction of NMO-ON recurrence after combined treatment was 0.895, which was significantly higher than those of 8-OHDG and VILIP-1 alone (0.588 and 0.682, P<0.05). Conclusion The elevated levels of baseline serum 8-OHDG and VILIP-1 in NMO-ON patients are associated with AQP4-IgG positivity and poor response to glucocorticoid therapy. High levels of 8-OHDG and VILIP-1 after treatment are associated with relapse. 8-OHDG and VILIP-1 can be used as markers for NMO-ON diagnosis and recurrence prediction.